查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1800960

多發性硬化症治療市場報告（按藥物、藥物類型、給藥途徑、配銷通路和地區）2025 年至 2033 年

Multiple Sclerosis Therapies Market Report by Drug, Drug Type, Route of Administration, Distribution Channel, and Region 2025-2033
出版日期: | 出版商: IMARC | 英文 120 Pages | 商品交期: 2-3個工作天內

價格

2024 年全球多發性硬化症治療市場規模達 279 億美元。展望未來， IMARC Group預計到 2033 年市場規模將達到 388 億美元，2025-2033 年期間的成長率 (CAGR) 為 3.52%。

多發性硬化症 (MS) 是一種慢性發炎性免疫介導疾病，可導致脊髓和腦神經細胞脫髓鞘、軸突斷裂和神經退化。一些常用的治療方法包括注射、口服和輸液藥物、肌肉鬆弛劑、抗憂鬱藥物以及物理治療。注射藥物，如干擾素BETA和醋酸格拉替雷，可透過皮下或肌肉注射；口服藥物包括富馬酸二甲酯、特立氟胺和克拉屈濱；輸液治療包括奧瑞珠單抗、那他珠單抗和阿崙單抗，可經由靜脈注射。這些藥物有助於控制症狀，最大限度地減少復發頻率，並控制患者的心率和血壓。

全球復發緩解型多發性硬化症 (RRMS)、原發性進展型多發性硬化症 (PPMS)、繼發進展型多發性硬化症 (SPMS) 和進展復發型多發性硬化症 (PRMS) 的盛行率不斷上升，是推動市場成長的關鍵因素之一。此外，老年人口的不斷成長也為市場成長提供了動力，老年人更容易患上此類疾病。醫療保健提供者正在廣泛使用免疫抑制劑來控制自體免疫攻擊並防止多發性硬化症患者復發。此外，各種技術進步，例如開發用於有效治療多發性硬化症的創新單株抗體、免疫調節劑、免疫抑制劑和干擾素，也是其他重要的成長誘導因素。此外，已開發國家和新興國家的政府都在進行宣傳活動，以提高民眾對現有治療替代方案的認知，這反過來又為市場創造了積極的前景。其他因素，包括廣泛的研究和開發 (R&D) 活動以及醫療保健基礎設施的改善，預計將進一步推動市場發展。

本報告回答的關鍵問題：

  • 全球多發性硬化症治療市場迄今表現如何？未來幾年將如何表現？
  • COVID-19 對全球多發性硬化症治療市場有何影響？
  • 主要的區域市場有哪些？
  • 根據藥品的不同，市場分佈如何？
  • 根據藥物類型，市場是如何分類的？
  • 根據行政路徑，市場如何分類？
  • 根據配銷通路，市場如何分類？
  • 該產業的價值鏈分為哪些階段？
  • 該行業的主要促進因素和挑戰是什麼？
  • 全球多發性硬化症治療市場的結構是怎麼樣的？主要參與者是誰？
  • 產業競爭程度如何？

目錄

第1章：前言

第2章：範圍與方法

  • 研究目標
  • 利害關係人
  • 資料來源
    • 主要來源
    • 次要來源
  • 市場評估
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第3章：執行摘要

第4章：簡介

第5章：全球多發性硬化症治療市場

  • 市場概覽
  • 市場表現
  • COVID-19的影響
  • 市場預測

第6章：市場區隔：依藥物

  • 免疫調節劑
    • 主要類型
      • 克帕松
      • Avonex/Plegridy
      • 吉爾尼亞
      • 泰薩布里
      • 倍他塞隆/Extavia
      • 特西菲德拉
      • 利比
      • 安比拉
  • 免疫抑制劑
    • 主要類型
      • 奧巴吉奧
      • 萊姆特拉達
      • 奧瑞珠單抗
      • 百日草

第7章：市場區隔：依藥物類型

  • 生物藥物
  • 小分子藥物

第8章：市場區隔：依行政途徑

  • 口服
  • 注射劑
  • 靜脈

第9章：市場區隔：按配銷通路

  • 醫院藥房
  • 零售藥局
  • 網路藥局

第10章：市場細分：按地區

  • 北美洲
    • 美國
    • 加拿大
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲

第 11 章：SWOT 分析

第 12 章：價值鏈分析

第 13 章：波特五力分析

第 14 章：價格分析

第 15 章：競爭格局

  • 市場結構
  • 關鍵參與者
  • 關鍵參與者簡介
    • Abbvie Inc.
    • Bayer Aktiengesellschaft
    • Biogen Inc.
    • Bristol-Myers Squibb Company
    • F. Hoffmann-La Roche AG (Roche Holding AG)
    • GlaxoSmithKline Plc
    • Merck & Co. Inc.
    • Novartis AG
    • Sanofi SA
    • Teva Pharmaceutical Industries Ltd.
Product Code: SR112025A2571

The global multiple sclerosis therapies market size reached USD 27.9 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 38.8 Billion by 2033, exhibiting a growth rate (CAGR) of 3.52% during 2025-2033.

Multiple sclerosis (MS) refers to a chronic and inflammatory immune-mediated condition that can cause demyelination, axonal transection and neurodegeneration of the nerve cells in the spinal cord and brain. Some of the commonly used therapies include the administration of injectable, oral and infused medicines, muscle relaxants, antidepressants and physical therapy. The injectable medication, such as Interferon-beta and Glatiramer acetate, are administered under the skin or into the muscle; oral medications include Dimethyl fumarate, Teriflunomide and Cladribine; and infusion treatments include Ocrelizumab, Natalizumab and Alemtuzumab, which are administered intravenously. These medicines aid in managing the symptoms to minimize the frequency of the relapses and control the heart rate and blood pressure of the patient.

The increasing prevalence of relapsing-remitting multiple sclerosis (RRMS), primary-progressive MS (PPMS), secondary-progressive MS (SPMS) and progressive-relapsing MS (PRMS) across the globe, is one of the key factors driving the growth of the market. Furthermore, the rising geriatric population, which is more susceptible to such ailments, is providing a thrust to the market growth. Healthcare providers are widely using immunosuppressants that control autoimmune attacks and prevent relapses among patients suffering from MS. Additionally, various technological advancements, such as the development of innovative monoclonal bodies, immunomodulators, immunosuppressants and interferons for the effective treatment of MS, are acting as other major growth-inducing factors. Apart from this, governments of both the developed and emerging countries are launching campaigns to increase awareness regarding the available treatment alternatives among the masses, which, in turn, is creating a positive outlook for the market. Other factors, including extensive research and development (R&D) activities, along with the improvements in the healthcare infrastructure, are anticipated to drive the market further.

Key Market Segmentation:

Breakup by Drug:

  • Immunomodulators
    • Copaxone
    • Avonex/Plegridy
    • Gilneya
    • Tysabri
    • Betaseron/Extavia
    • Tecifidera
    • Rebif
    • Ampyra
  • Immunosuppressants
    • Aubagio
    • Lemtrada
    • Ocrelizumab
    • Zinbryta

Breakup by Drug Type:

  • Biologic Drugs
  • Small Molecule Drugs

Breakup by Route of Administration:

  • Oral
  • Injectable
  • Intravenous

Breakup by Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Breakup by Region:

  • North America
    • United States
    • Canada
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

Competitive Landscape:

The report has also analysed the competitive landscape of the market with some of the key players being Abbvie Inc., Bayer Aktiengesellschaft, Biogen Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche AG (Roche Holding AG), GlaxoSmithKline Plc, Merck & Co. Inc., Novartis AG, Sanofi S.A. and Teva Pharmaceutical Industries Ltd.

Key Questions Answered in This Report:

  • How has the global multiple sclerosis therapies market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global multiple sclerosis therapies market?
  • What are the key regional markets?
  • What is the breakup of the market based on the drug?
  • What is the breakup of the market based on the drug type?
  • What is the breakup of the market based on the route of administration?
  • What is the breakup of the market based on the distribution channel?
  • What are the various stages in the value chain of the industry?
  • What are the key driving factors and challenges in the industry?
  • What is the structure of the global multiple sclerosis therapies market and who are the key players?
  • What is the degree of competition in the industry?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Multiple Sclerosis Therapies Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Drug

  • 6.1 Immunomodulators
    • 6.1.1 Market Trends
    • 6.1.2 Major Types
      • 6.1.2.1 Copaxone
      • 6.1.2.2 Avonex/Plegridy
      • 6.1.2.3 Gilneya
      • 6.1.2.4 Tysabri
      • 6.1.2.5 Betaseron/Extavia
      • 6.1.2.6 Tecifidera
      • 6.1.2.7 Rebif
      • 6.1.2.8 Ampyra
    • 6.1.3 Market Forecast
  • 6.2 Immunosuppressants
    • 6.2.1 Market Trends
    • 6.2.2 Major Types
      • 6.2.2.1 Aubagio
      • 6.2.2.2 Lemtrada
      • 6.2.2.3 Ocrelizumab
      • 6.2.2.4 Zinbryta
    • 6.2.3 Market Forecast

7 Market Breakup by Drug Type

  • 7.1 Biologic Drugs
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Small Molecule Drugs
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast

8 Market Breakup by Route of Administration

  • 8.1 Oral
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Injectable
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Intravenous
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by Distribution Channel

  • 9.1 Hospital Pharmacies
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Retail Pharmacies
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Online Pharmacies
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 United States
      • 10.1.1.1 Market Trends
      • 10.1.1.2 Market Forecast
    • 10.1.2 Canada
      • 10.1.2.1 Market Trends
      • 10.1.2.2 Market Forecast
  • 10.2 Asia Pacific
    • 10.2.1 China
      • 10.2.1.1 Market Trends
      • 10.2.1.2 Market Forecast
    • 10.2.2 Japan
      • 10.2.2.1 Market Trends
      • 10.2.2.2 Market Forecast
    • 10.2.3 India
      • 10.2.3.1 Market Trends
      • 10.2.3.2 Market Forecast
    • 10.2.4 South Korea
      • 10.2.4.1 Market Trends
      • 10.2.4.2 Market Forecast
    • 10.2.5 Australia
      • 10.2.5.1 Market Trends
      • 10.2.5.2 Market Forecast
    • 10.2.6 Indonesia
      • 10.2.6.1 Market Trends
      • 10.2.6.2 Market Forecast
    • 10.2.7 Others
      • 10.2.7.1 Market Trends
      • 10.2.7.2 Market Forecast
  • 10.3 Europe
    • 10.3.1 Germany
      • 10.3.1.1 Market Trends
      • 10.3.1.2 Market Forecast
    • 10.3.2 France
      • 10.3.2.1 Market Trends
      • 10.3.2.2 Market Forecast
    • 10.3.3 United Kingdom
      • 10.3.3.1 Market Trends
      • 10.3.3.2 Market Forecast
    • 10.3.4 Italy
      • 10.3.4.1 Market Trends
      • 10.3.4.2 Market Forecast
    • 10.3.5 Spain
      • 10.3.5.1 Market Trends
      • 10.3.5.2 Market Forecast
    • 10.3.6 Russia
      • 10.3.6.1 Market Trends
      • 10.3.6.2 Market Forecast
    • 10.3.7 Others
      • 10.3.7.1 Market Trends
      • 10.3.7.2 Market Forecast
  • 10.4 Latin America
    • 10.4.1 Brazil
      • 10.4.1.1 Market Trends
      • 10.4.1.2 Market Forecast
    • 10.4.2 Mexico
      • 10.4.2.1 Market Trends
      • 10.4.2.2 Market Forecast
    • 10.4.3 Others
      • 10.4.3.1 Market Trends
      • 10.4.3.2 Market Forecast
  • 10.5 Middle East and Africa
    • 10.5.1 Market Trends
    • 10.5.2 Market Breakup by Country
    • 10.5.3 Market Forecast

11 SWOT Analysis

  • 11.1 Overview
  • 11.2 Strengths
  • 11.3 Weaknesses
  • 11.4 Opportunities
  • 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 Abbvie Inc.
      • 15.3.1.1 Company Overview
      • 15.3.1.2 Product Portfolio
      • 15.3.1.3 Financials
      • 15.3.1.4 SWOT Analysis
    • 15.3.2 Bayer Aktiengesellschaft
      • 15.3.2.1 Company Overview
      • 15.3.2.2 Product Portfolio
      • 15.3.2.3 Financials
      • 15.3.2.4 SWOT Analysis
    • 15.3.3 Biogen Inc.
      • 15.3.3.1 Company Overview
      • 15.3.3.2 Product Portfolio
      • 15.3.3.3 Financials
      • 15.3.3.4 SWOT Analysis
    • 15.3.4 Bristol-Myers Squibb Company
      • 15.3.4.1 Company Overview
      • 15.3.4.2 Product Portfolio
      • 15.3.4.3 Financials
      • 15.3.4.4 SWOT Analysis
    • 15.3.5 F. Hoffmann-La Roche AG (Roche Holding AG)
      • 15.3.5.1 Company Overview
      • 15.3.5.2 Product Portfolio
      • 15.3.5.3 SWOT Analysis
    • 15.3.6 GlaxoSmithKline Plc
      • 15.3.6.1 Company Overview
      • 15.3.6.2 Product Portfolio
      • 15.3.6.3 Financials
      • 15.3.6.4 SWOT Analysis
    • 15.3.7 Merck & Co. Inc.
      • 15.3.7.1 Company Overview
      • 15.3.7.2 Product Portfolio
      • 15.3.7.3 Financials
      • 15.3.7.4 SWOT Analysis
    • 15.3.8 Novartis AG
      • 15.3.8.1 Company Overview
      • 15.3.8.2 Product Portfolio
      • 15.3.8.3 Financials
      • 15.3.8.4 SWOT Analysis
    • 15.3.9 Sanofi S.A.
      • 15.3.9.1 Company Overview
      • 15.3.9.2 Product Portfolio
      • 15.3.9.3 Financials
      • 15.3.9.4 SWOT Analysis
    • 15.3.10 Teva Pharmaceutical Industries Ltd.
      • 15.3.10.1 Company Overview
      • 15.3.10.2 Product Portfolio
      • 15.3.10.3 Financials
      • 15.3.10.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Multiple Sclerosis Therapies Market: Major Drivers and Challenges
  • Figure 2: Global: Multiple Sclerosis Therapies Market: Sales Value (in Billion USD), 2019-2024
  • Figure 3: Global: Multiple Sclerosis Therapies Market: Breakup by Drug (in %), 2024
  • Figure 4: Global: Multiple Sclerosis Therapies Market: Breakup by Drug Type (in %), 2024
  • Figure 5: Global: Multiple Sclerosis Therapies Market: Breakup by Route of Administration (in %), 2024
  • Figure 6: Global: Multiple Sclerosis Therapies Market: Breakup by Distribution Channel (in %), 2024
  • Figure 7: Global: Multiple Sclerosis Therapies Market: Breakup by Region (in %), 2024
  • Figure 8: Global: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Billion USD), 2025-2033
  • Figure 9: Global: Multiple Sclerosis Therapies (Immunomodulators) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 10: Global: Multiple Sclerosis Therapies (Immunomodulators) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 11: Global: Multiple Sclerosis Therapies (Immunosuppressants) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 12: Global: Multiple Sclerosis Therapies (Immunosuppressants) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 13: Global: Multiple Sclerosis Therapies (Biologic Drugs) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 14: Global: Multiple Sclerosis Therapies (Biologic Drugs) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 15: Global: Multiple Sclerosis Therapies (Small Molecule Drugs) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 16: Global: Multiple Sclerosis Therapies (Small Molecule Drugs) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 17: Global: Multiple Sclerosis Therapies (Oral) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 18: Global: Multiple Sclerosis Therapies (Oral) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 19: Global: Multiple Sclerosis Therapies (Injectable) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 20: Global: Multiple Sclerosis Therapies (Injectable) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 21: Global: Multiple Sclerosis Therapies (Intravenous) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 22: Global: Multiple Sclerosis Therapies (Intravenous) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 23: Global: Multiple Sclerosis Therapies (Hospital Pharmacies) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 24: Global: Multiple Sclerosis Therapies (Hospital Pharmacies) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 25: Global: Multiple Sclerosis Therapies (Retail Pharmacies) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 26: Global: Multiple Sclerosis Therapies (Retail Pharmacies) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 27: Global: Multiple Sclerosis Therapies (Online Pharmacies) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 28: Global: Multiple Sclerosis Therapies (Online Pharmacies) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 29: North America: Multiple Sclerosis Therapies Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 30: North America: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 31: United States: Multiple Sclerosis Therapies Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 32: United States: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 33: Canada: Multiple Sclerosis Therapies Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 34: Canada: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 35: Asia Pacific: Multiple Sclerosis Therapies Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 36: Asia Pacific: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 37: China: Multiple Sclerosis Therapies Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 38: China: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 39: Japan: Multiple Sclerosis Therapies Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 40: Japan: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 41: India: Multiple Sclerosis Therapies Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 42: India: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 43: South Korea: Multiple Sclerosis Therapies Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 44: South Korea: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 45: Australia: Multiple Sclerosis Therapies Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 46: Australia: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 47: Indonesia: Multiple Sclerosis Therapies Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 48: Indonesia: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 49: Others: Multiple Sclerosis Therapies Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 50: Others: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 51: Europe: Multiple Sclerosis Therapies Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 52: Europe: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 53: Germany: Multiple Sclerosis Therapies Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 54: Germany: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 55: France: Multiple Sclerosis Therapies Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 56: France: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 57: United Kingdom: Multiple Sclerosis Therapies Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 58: United Kingdom: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 59: Italy: Multiple Sclerosis Therapies Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 60: Italy: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 61: Spain: Multiple Sclerosis Therapies Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 62: Spain: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 63: Russia: Multiple Sclerosis Therapies Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 64: Russia: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 65: Others: Multiple Sclerosis Therapies Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 66: Others: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 67: Latin America: Multiple Sclerosis Therapies Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 68: Latin America: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 69: Brazil: Multiple Sclerosis Therapies Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 70: Brazil: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 71: Mexico: Multiple Sclerosis Therapies Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 72: Mexico: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 73: Others: Multiple Sclerosis Therapies Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 74: Others: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 75: Middle East and Africa: Multiple Sclerosis Therapies Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 76: Middle East and Africa: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 77: Global: Multiple Sclerosis Therapies Industry: SWOT Analysis
  • Figure 78: Global: Multiple Sclerosis Therapies Industry: Value Chain Analysis
  • Figure 79: Global: Multiple Sclerosis Therapies Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Multiple Sclerosis Therapies Market: Key Industry Highlights, 2024 and 2033
  • Table 2: Global: Multiple Sclerosis Therapies Market Forecast: Breakup by Drug (in Million USD), 2025-2033
  • Table 3: Global: Multiple Sclerosis Therapies Market Forecast: Breakup by Drug Type (in Million USD), 2025-2033
  • Table 4: Global: Multiple Sclerosis Therapies Market Forecast: Breakup by Route of Administration (in Million USD), 2025-2033
  • Table 5: Global: Multiple Sclerosis Therapies Market Forecast: Breakup by Distribution Channel (in Million USD), 2025-2033
  • Table 6: Global: Multiple Sclerosis Therapies Market Forecast: Breakup by Region (in Million USD), 2025-2033
  • Table 7: Global: Multiple Sclerosis Therapies Market Structure
  • Table 8: Global: Multiple Sclerosis Therapies Market: Key Player